Publications, Pharmaceutical

Why it is time to think differently about Nasal delivery of Biologics

COVID-19 has reinvigorated interest in the advantages of nasal delivery for a pharmaceutical industry already embracing a shift towards biologics.

Download Publication
Author(s): Gemma Budd Irene Rossi
4 Apr 2022

This article considers the challenges and potential benefits of combining the two. The nasal delivery of biologics offers considerable potential for both local and systemic action and for direct access to the brain and CNS to address currently unmet therapeutic need. The unique features of biologics are discussed with reference to the associated difficulties of nasal delivery and the benefits of partnership with experts such as Aptar Pharma is highlighted. Work on the development of vaccines and prophylactics for COVID-19 illustrates what is achievable.

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

13 Mar 2024

In Silico Modelling for Orally Inhaled Drug Development (OINDP)

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
7 Mar 2024

Sustainable Propellants and Bioequivalence Innovation in OINDPs

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
26 Feb 2024

Intranasal Delivery of Monoclonal Antibodies via Dry Powder

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
2 Feb 2024

Systemic Nasal Drug Delivery for CNS Diseases and Beyond

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 4 5 6 27

Request Access

Close

Requesting access to Why it is time to think differently about Nasal delivery of Biologics.

  • This field is for validation purposes and should be left unchanged.
Back To Top